Stocktoria
Novo Nordisk A/S NOVO-B.CO
Novo Nordisk A/S statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (kr 174.39); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Novo Nordisk A/S trades at about 12.8× earnings — below its 10-year norm (10-year range 16×–77.2×, median 41.6×).
Shaded band = 10-year range (16×–77.2×); dot = today's 12.8×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 81.0% | 84.7% | 84.6% | 83.9% |
| Operating margin | 41.3% | 44.2% | 44.2% | 42.3% |
| Net margin | 33.1% | 34.8% | 36.0% | 31.4% |
| FCF margin | 9.4% | 24.0% | 30.1% | 36.2% |
| Return on assets | 18.9% | 21.7% | 26.6% | 23.0% |
| Return on equity | 52.8% | 70.4% | 78.5% | 66.5% |
| Debt / equity | 0.58× | 0.59× | 0.15× | 0.25× |
| Current ratio | 0.80 | 0.74 | 0.82 | 0.89 |
Computed from company filings · DK · as of 2025-12-31. Figures in DKK. Facts plus Stocktoria's own computed scores — not investment advice.